The clinical-stage biotech that appointed a 'proven scaling CEO' pre-Phase-3 announces a capital raise or dilutive financing within 8 weeks, not a partnership.

A psychedelic drug company that recently brought in a CEO famous for scaling businesses is expected to announce a fundraise — meaning it will issue new shares and dilute existing shareholders — within about two months of that hire. Companies hire 'scaling' executives when they need money and want to look confident doing it. Current shareholders end up owning a smaller slice of the company.

Scaling CEOs are hired to raise and commercialize, not to shepherd science. Pre-pivotal cash-runway math forces dilution. Follows textbook catalyst sequencing.